TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30638411

Group type: EXPERIMENTAL
Intervention: Raft-forming chewable tablets containing Nizatidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized formulations using sodium alginate, calcium carbonate, and sodium bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct compression technique and wet granulation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X-Ray evaluation of raft
Number of subjects: 0
Study: 28296717

Group type: EXPERIMENTAL
Intervention: Processed AWA (with gamma irradiation and decellularization)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Unprocessed AWA (fresh, unprocessed)
Number of subjects: 6
Study: 26026350

Group type: EXPERIMENTAL
Intervention: Dipyrone (25 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meloxicam (0.2 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dipyrone-Meloxicam (25 mg/kg and 0.2 mg/kg, respectively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (physiological saline)
Number of subjects: 40
Study: 22939006

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21236452

Group type: EXPERIMENTAL
Intervention: 1 ED(95) of rocuronium (0.3 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2 ED(95) of rocuronium
Number of subjects: 80
Study: 18320301

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 27
Study: 21980939

Group type: EXPERIMENTAL
Intervention: Breast-feeding (observational analysis)
Number of subjects: 13889

Group type: COMPARATOR
Intervention: Randomised experimental group
Number of subjects: 13889
Study: 16191718

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (skills training and reinforcement)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Limited intervention (initial skills training followed by advice)
Number of subjects: 53
Study: 11827684

Group type: EXPERIMENTAL
Intervention: Human urotensin II (hUII) infusion at doses of 100 and 300 pmol min(‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Human urotensin II (hUII) infusion with nitric oxide clamp
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Local administration of hUII (3‐300 pmol min(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall systemic hemodynamics
Number of subjects: 15
Study: 9881390

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting filter (group L, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No leucocyte filter (group C, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (L and C)
Number of subjects: 40
Study: 7979954

Group type: EXPERIMENTAL
Intervention: PGG-glucan at a dose of 0.1 mg/kg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PGG-glucan at a high dose (1.0 mg/kg or 2.0 mg/kg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (including PGG-glucan and placebo)
Number of subjects: 67
Study: 3377942

Group type: EXPERIMENTAL
Intervention: Fentanyl i.v. at 100 micrograms h‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl i.v. at 125 micrograms h‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS-fentanyl)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11686263

Group type: EXPERIMENTAL
Intervention: Verbal information from an adult
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal information from a teacher or peer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video information
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information given
Number of subjects: 0
Study: 30882730

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 0
Study: 29630034

Group type: EXPERIMENTAL
Intervention: IV DEX 2.0 μg/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: IV normal saline (control)
Number of subjects: 72
Study: 25896582

Group type: EXPERIMENTAL
Intervention: Violent Video Games (VVGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-violent Video Games
Number of subjects: 0
Study: 25252480

Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no calcium and phosphorus supplementation)
Number of subjects: 40
Study: 22357989

Group type: EXPERIMENTAL
Intervention: CAC score of 1-100
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: CAC score of 101-1000
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: CAC score of more than 1000
Number of subjects: 958
Study: 20558553

Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 66
Study: 16494935

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with Panavia F
Number of subjects: 16

Group type: COMPARATOR
Intervention: Panavia F
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sustained seating pressure for 3 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sustained seating pressure for 5 seconds
Number of subjects: 16
Study: 14993489

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (10-150 microg) administered once a week or once every 2 weeks
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (i.v.)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (s.c.)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (for subjects with baseline haemoglobin < 11 g/dl)
Number of subjects: 1502
Study: 11641677

Group type: EXPERIMENTAL
Intervention: Vaginally administered misoprostol (25 microg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Oral plus vaginal misoprostol (25 microg orally, 25 microg vaginally)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (25 microg)
Number of subjects: 330
Study: 9695781

Group type: EXPERIMENTAL
Intervention: Live tularemia vaccine (LTV) immunization 15-20 days before surgery
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard uterine extirpation or with adnexa (control group)
Number of subjects: 194
Study: 7723271

Group type: EXPERIMENTAL
Intervention: Complex diet including proteins
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Immunomodulation agents
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation
Number of subjects: 932
Study: 2723257

Group type: EXPERIMENTAL
Intervention: Educational movie on AIDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational movie on first aid
Number of subjects: 0
Study: 30309389

Group type: EXPERIMENTAL
Intervention: PQ912 800 mg bid for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28809743

Group type: EXPERIMENTAL
Intervention: Asunaprevir (100 mg twice daily) + Daclatasvir (60 mg once daily) for 24 weeks
Number of subjects: 49
Study: 26298715

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255

Group type: COMPARATOR
Intervention: Systemic corticosteroid therapy
Number of subjects: 255
Study: 23121459

Group type: EXPERIMENTAL
Intervention: Thermo-reversible sustained-release green tea catechin gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 21515474

Group type: EXPERIMENTAL
Intervention: Continuous infusion of dexmedetomidine at 0.2 µg·kg(‐1)·h(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study: 18435868

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (types 6/11/16/18) L1 virus‐like‐particle vaccine
Number of subjects: 72
Study: 16950199

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (both doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (all dosing regimes)
Number of subjects: 0
Study: 12969017

Group type: EXPERIMENTAL
Intervention: H. pylori infection (no treatment prior to end of follow-up)
Number of subjects: 47
Study: 10530493

Group type: EXPERIMENTAL
Intervention: AMT group (amoxycillin + metronidazole + tagamet)
Number of subjects: 96

Group type: COMPARATOR
Intervention: OA group (omeprazole + amoxycillin)
Number of subjects: 96
Study: 8684767

Group type: EXPERIMENTAL
Intervention: Microcolposcopy before excisional treatment
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no microcolposcopy)
Number of subjects: 330
Study: 1853617

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment (250 mg daily) for 3 months starting from the seventh postoperative day
Number of subjects: 144

Group type: COMPARATOR
Intervention: No ASA treatment (control group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 144
Study: 6603042

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole, 2 tabs twice a day for 14 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Trimethoprim, 250 mg twice a day for 14 days
Number of subjects: 53
Study: 31842577

Group type: EXPERIMENTAL
Intervention: Resistance training program with ADT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ADT without exercise training)
Number of subjects: 0
Study: 28414522

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 60
Study: 27158001

Group type: EXPERIMENTAL
Intervention: OCT imaging at 6 months (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCT imaging at 9 months (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCT imaging at 12 months (group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of uncovered struts ratio <30%
Number of subjects: 30
Study: 24552391

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 22619082

Group type: EXPERIMENTAL
Intervention: DAFNE structured education program
Number of subjects: 639
Study: 19639919

Group type: EXPERIMENTAL
Intervention: Parkell film
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulating silk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Articulating paper
Number of subjects: 0

Group type: COMPARATOR
Intervention: T‐Scan foil
Number of subjects: 0
Study: 17222649

Group type: EXPERIMENTAL
Intervention: 80 mg zinc
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 3640
Study: 15583956

Group type: EXPERIMENTAL
Intervention: 20 mg budipine (t.i.d.)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12485319

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10066843

Group type: EXPERIMENTAL
Intervention: rtPA treatment
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Both treatments (rtPA and placebo)
Number of subjects: 450
Study: 7733031

Group type: EXPERIMENTAL
Intervention: Raw potato starch (54% type II RS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pregelatinized starch (0% RS)
Number of subjects: 15
Study: 2292534

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg bd orally for 10 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g daily im for 10 days
Number of subjects: 96
Study: 6789356

Group type: EXPERIMENTAL
Intervention: Pentobarbital (three doses)
Number of subjects: 0
Study: 29741201

Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation (FPP®) 9g/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27105646

Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention package
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 462
Study: 25492830

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg/d, increased to 10 mg if BP control not achieved at 4 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 80
Study: 22571202

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy (10 mg per day for the first 3 months, increased to 15 mg if tolerated)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 20821979

Group type: EXPERIMENTAL
Intervention: Reamberin (antioxidant preparation)
Number of subjects: 160

Group type: COMPARATOR
Intervention: CAF scheme
Number of subjects: 160

Group type: COMPARATOR
Intervention: AVCFM scheme
Number of subjects: 160
Study: 18400281

Group type: EXPERIMENTAL
Intervention: Diet emphasizing plant-based foods and fish, 11 dietary and cooking classes with mindfulness practice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study: 16155034

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg kg(‐1) min(‐1) (Group R, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Group S, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 12574731

Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-allergen diet
Number of subjects: 0
Study: 11217557

Group type: EXPERIMENTAL
Intervention: Prostatron 2.5
Number of subjects: 46
Study: 8823483

Group type: EXPERIMENTAL
Intervention: 5FU, EPI, MMC with Leucovorin (group B)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 5FU, EPI, MMC without Leucovorin (group A)
Number of subjects: 88
Study: 1563213

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of furosemide (4 mg/hr for 8 hours after an 8 mg loading dose, total dose 40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus injection of furosemide (40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of furosemide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus injection of furosemide
Number of subjects: 8
Study: 3890435

Group type: EXPERIMENTAL
Intervention: Indoprofen (400 mg, intravenous)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Oxicone (10 mg, intramuscular) combined with papaverine (20 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Oxicone (10 mg, intramuscular)
Number of subjects: 94
Study: 3013766

Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 25 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 50 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day for 6 weeks
Number of subjects: 13
Study: 31222812

Group type: EXPERIMENTAL
Intervention: 3L-Mind-Training programme for 6 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Regular health promotion activities (Control)
Number of subjects: 126
Study: 29885154

Group type: EXPERIMENTAL
Intervention: Seidl method for estimating blood alcohol concentration (eBAC)
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Refined calculation of eBAC
Number of subjects: 2282
Study: 27473311

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Art Therapy (MBAT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 26246937

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 136
Study: 22642891

Group type: EXPERIMENTAL
Intervention: Choice Reaction Time (RT) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple Reaction Time (RT) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choice RT group in Simple RT condition
Number of subjects: 0
Study: 20483019

Group type: EXPERIMENTAL
Intervention: Isolite system (IS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cotton roll isolation (CRI)
Number of subjects: 48
Study: 18986062

Group type: EXPERIMENTAL
Intervention: Form information as the main clue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Space information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Only colour information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three clues (symbol, location, colour) available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Form information as the main clue in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No form information used in Experiment 2
Number of subjects: 0
Study: 16419569

Group type: EXPERIMENTAL
Intervention: SPECT evaluation of regional cerebral blood flow (rCBF)
Number of subjects: 32
Study: 12867355

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12338

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12338
Study: 11030260

Group type: EXPERIMENTAL
Intervention: Client-centered approach with an average of 14 hours of service for youth and 27 hours for teenagers.
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Control group receiving only 2-5 hours of service.
Number of subjects: 1732
Study: 8884536

Group type: EXPERIMENTAL
Intervention: Nasal administration of bromocriptine (0.8 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral administration of bromocriptine (2.5 mg)
Number of subjects: 20
Study: 1530171

Group type: EXPERIMENTAL
Intervention: Flumazenil during midazolam-narcotic anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane-nitrous oxide anesthesia
Number of subjects: 20
Study: 3890781

Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonselective shunt
Number of subjects: 55
Study: 30610759

Group type: EXPERIMENTAL
Intervention: Cell salvage plus additional WBC depletion filter
Number of subjects: 364

Group type: COMPARATOR
Intervention: Cell salvage
Number of subjects: 364
Study: 30267441

Group type: EXPERIMENTAL
Intervention: Postoperative cefpodoxime for 7 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 150
Study: 24969964

Group type: EXPERIMENTAL
Intervention: Quarterly group medical visits
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quarterly CRRC individual clinic visits
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 200
Study: 22365565

Group type: EXPERIMENTAL
Intervention: Propranolol infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion with remifentanil
Number of subjects: 10
Study: 20154079

Group type: EXPERIMENTAL
Intervention: CT‐ANPB (CT scan-guided Abrams needle pleural biopsy)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Thoracoscopy
Number of subjects: 124
Study: 17885351

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonpenetrating 'placebo' needle
Number of subjects: 2
Study: 16216719

Group type: EXPERIMENTAL
Intervention: Plant sterol diet (PS diet)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Carbohydrate diet (CHO diet)
Number of subjects: 29

Group type: COMPARATOR
Intervention: New Zealand diet (NZ diet)
Number of subjects: 29
Study: 12456232

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/d)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 2531
Study: 11064623

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine plus hyaluronidase 300 IU ml-1
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% bupivacaine/2% lidocaine plus 50 IU ml-1 hyaluronidase
Number of subjects: 80
Study: 8650942

Group type: EXPERIMENTAL
Intervention: Mildly protein restricted diet (0.7 g/kg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal protein diet (1.2 g/kg/day)
Number of subjects: 14
Study: 1435170

Group type: EXPERIMENTAL
Intervention: Low impact exercise group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High impact exercise group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control nonexercising group
Number of subjects: 15
Study: 3933897

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30433809

Group type: EXPERIMENTAL
Intervention: Sleep Fragmentation (SF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sleep Deprivation (SD)
Number of subjects: 50
Study: 28968794

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 25913602

Group type: EXPERIMENTAL
Intervention: Mandatory public reporting of central line-associated bloodstream infection (CLABSI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hospitals without mandatory public reporting
Number of subjects: 17
Study: 23394867

Group type: COMPARATOR
Intervention: Steroid treatment (S group)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combination treatment with steroid and antiviral agent (S+A group)
Number of subjects: 206
Study: 21459795

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation
Number of subjects: 243

Group type: COMPARATOR
Intervention: Conventional post-remission therapy
Number of subjects: 243
Study: 18280811

Group type: EXPERIMENTAL
Intervention: Low-activity genotype (AG, AA) in non-diabetic subjects
Number of subjects: 198

Group type: COMPARATOR
Intervention: High-activity genotype (G/G) in non-diabetic subjects
Number of subjects: 198

Group type: COMPARATOR
Intervention: Type 2 DM subjects
Number of subjects: 198
Study: 16531708

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (platinum-based chemotherapy or UFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0